Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that turns cutting-edge science into medicines for some of the world’s most serious diseases. The company has a market capitalization of $85.3 billion, and its portfolio spans eye diseases, immunology and inflammation, cancer, cardiovascular and metabolic disorders, neurological conditions, and rare diseases, with key medicines including EYLEA, Dupixent, and Libtayo.  

Regeneron has been on a tear over the past year, with the stock surging 45.6% and leaving the S&P 500 Index’s ($SPX) 18.7% return far behind. However, the momentum has cooled somewhat in 2026, with REGN up 8% year to date compared to the index’s 12.2% gain. 

REGN has lagged behind the State Street SPDR S&P Biotech ETF (XBI), which has surged 90.5% over the past 52 weeks and 38.7% this year.

On July 30, Regeneron delivered a strong Q2 2026 that gave the stock a 6.2% post-earnings boost, as its newer growth engines continued to pick up the slack from its aging EYLEA franchise. Revenue rose 16.7% year over year to $4.29 billion, while non-GAAP EPS climbed 10.9% to $14.29, extending the company’s streak of double-digit growth. Dupixent stole the spotlight, with global sales jumping 38% to a record $6 billion and giving Regeneron’s collaboration income a major lift.

The company also entered its next chapter on firmer financial footing, fully repaying the Sanofi Development Balance and removing a lingering drag on future profits. Additionally, its pipeline kept moving forward, with cemdisiran accepted for regulatory review in the U.S. and Europe for generalized myasthenia gravis.

For the current year ending in December 2026, analysts expect Regeneron’s EPS to rise 24.6% YoY to $44.25 on a diluted basis. The company’s earnings surprise history is impressive. It surpassed the consensus estimate in each of the last four quarters.

Among the 29 analysts covering REGN stock, the consensus is a “Moderate Buy.” That’s based on 17 “Strong Buy” ratings, two “Moderate Buys,” and ten “Holds.” 

The configuration is more bearish than two months ago, when the stock had 18 “Strong Buy” suggestions. 

On Aug. 21, Scotiabank analyst Louise Chen maintained a “Hold” rating on Regeneron and set a $770 price target, signaling a cautious stance on the stock despite its strong recent performance. 

REGN’s mean price target of $852.18 implies a 2.2% premium to its current price. Its Street-high target of $1,030 suggests a 23.6% potential upside.